Legal Representation
Attorney
Chun T. Wright
USPTO Deadlines
Next Deadline
124 days remaining
NOA E-Mailed - SOU Required
Due Date
June 05, 2026
Extension Available
Until December 05, 2026
Application History
35 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Dec 3, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Dec 2, 2025 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| Dec 2, 2025 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| Dec 2, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Sep 19, 2025 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| May 23, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| May 22, 2025 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| May 22, 2025 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| May 22, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Dec 12, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Dec 12, 2024 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Nov 26, 2024 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Nov 26, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Aug 14, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Aug 14, 2024 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Jun 5, 2024 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Aug 12, 2024 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Jun 6, 2024 | TPEX | I | SOU EXTENSION RECEIVED WITH TEAS PETITION | Loading... |
| Jun 6, 2024 | NREV | E | NOTICE OF REVIVAL - E-MAILED | Loading... |
| Jun 6, 2024 | PETG | O | PETITION TO REVIVE-GRANTED | Loading... |
| Jun 6, 2024 | PROA | I | TEAS PETITION TO REVIVE RECEIVED | Loading... |
| Dec 5, 2023 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Oct 10, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Oct 10, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Sep 20, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Sep 5, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jul 21, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jul 21, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jul 21, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Apr 21, 2023 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Apr 21, 2023 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Apr 21, 2023 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Apr 20, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jul 25, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jul 9, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 001
Cells, sub-cellular fractions, antibodies, reagents and culture media for scientific, laboratory, and research use; Immune cells isolated from leukapheresis collections by immunomagnetic or density gradient separation from normal, healthy human donors for scientific, laboratory, and research use; Human AB serum derived from either plasma or whole blood from normal, healthy male human donors with AB blood type for scientific, laboratory, research, and further manufacturing use
Class 039
Distribution services, namely, delivery of cells, sub-cellular fractions, antibodies, reagents, culture media, and biological tissue, namely, immune cells, bone marrow, and pooled serum from either plasma or whole blood
Class 042
Manufacturing and processing of cells in the field of cell therapies for medical and scientific research; Bone marrow aspiration for medical and scientific research; Research and development services in the field of cell therapies; Custom production and manufacture of advanced therapeutics such as cell and gene therapies for others for medical and scientific research; Leukapheresis collections from normal, healthy human donors for use as a source material for manufacturing and processing of cells for laboratory, medical and scientific research; Cell therapy services, namely, manufacturing and processing of Human AB serum and leukapheresis material for human biotherapies and in vivo therapies for laboratory, medical and scientific research; Medical services for cell sampling and isolation, namely, leukapheresis medical treatment services for laboratory, medical and scientific research
Additional Information
Pseudo Mark
VIVO START
Classification
International Classes
001
039
042